1	A simple asthma prediction tool for pre-school children with wheeze or cough
2	
3	Anina M Pescatore, MSc, ¹ Cristian M Dogaru, MD, PhD, ¹ Lutz Duembgen, PhD ² ,
4	MSc, ¹ Michael Silverman, MD, ³ Erol Gaillard, MD, ³ Ben D Spycher, PhD, ^{1*}
5	Claudia E Kuehni, MD, MSc ^{1*}
6	
7	¹ Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern,
8	Switzerland;
9	² Institute of Mathematical Statistics and Actuarial Science, University of Bern, Bern,
10	Switzerland
11	³ Department of Infection, Immunity & Inflammation, University of Leicester,
12	Leicester, United Kingdom
13	* Shared last authorship
14	
15	Correspondence
16	Prof. Claudia E. Kuehni
17	Institute of Social and Preventive Medicine
18	Finkenhubelweg 11, CH-3012 Bern, Switzerland
19	Tel.: +41 (0)31 631 35 07
20	Fax: +41 (0)31 631 35 20
21	E-mail: kuehni@ispm.unibe.ch
22	
23	
24	
25	

26 Funding

- 27 Swiss National Science Foundation (PDFMP3-123162 and 3200B0-122341) and
- Asthma UK 07/048. Ben Spycher is the recipient of a European Respiratory
- 29 Society/Marie Curie Joint Research Fellowship (MC 1614-2010).
- 30

31 Word count

- 32 3242/3500
- 33

34 Key words

- Asthma, wheeze, cough, children, prediction, prognosis, persistence, longitudinal,
- 36 cohort study
- 37

38 Clinical Implications

- 39 The proposed asthma prediction tool is simple and uses information that is non-
- 40 invasive and easy to assess. This makes it an ideal instrument for use in clinical
- 41 practice and research.

42

43 Capsule summary

- 44 We have developed a simple tool to predict later asthma in preschool children
- suffering from wheeze or cough. Its simplicity and internal validity facilitate use in
- 46 clinical practice and epidemiological research.

47

48 Abbreviations

- 49 ROC curve: receiver operating characteristic curve
- 50 AUC: area under the ROC curve

- 51 HL test: Hosmer-Lemeshow goodness-of-fit-test
- 52 OR: odds ratio

53

54 Abstract

Background: Many preschool children suffer from wheeze or cough, but only some
have asthma later. Existing prediction tools are difficult to apply in clinical practice or
exhibit methodological weaknesses.

58 **Objective:** To develop a simple and robust tool for predicting asthma at school-age 59 in pre-school children with wheeze or cough.

Methods: From a population-based cohort in Leicestershire, UK, we included 1-3 60 year-olds seeing a doctor for wheeze or cough, and assessed prevalence of asthma 61 five years later. We considered only non-invasive predictors that are easy to assess 62 in primary care: demographic and perinatal data, eczema, various upper and lower 63 respiratory symptoms and family history of atopy. We developed a model using 64 logistic regression, avoided over-fitting with a LASSO-penalty, and then simplified it 65 to a practical tool. We performed internal validation and assessed its predictive 66 performance using the scaled Brier score and the area under receiver operating 67 characteristic curve (AUC). 68

Results: Of 1226 symptomatic children with follow-up information, 345 (28%) had asthma 5 years later. The tool is based on 10 predictors yielding a total score between 0 and 15: sex, age, wheeze without colds, wheeze frequency, activity disturbance, shortness of breath, exercise-related and aeroallergen-related wheeze/cough, eczema, and parental history of asthma/bronchitis. The scaled Brier scores for the internally validated model and tool were 0.20 and 0.16, and the AUCs were 0.76 and 0.74, respectively.

76 **Conclusion:**

This simple, low-cost and non-invasive tool has good potential for identifying pre-

school children at risk for later asthma and should be tested in other populations.

79 Introduction

Many preschool children present to primary care with recurrent wheeze or cough. 80 These symptoms are a burden to families and lead to treatment with inhalers, 81 antibiotics or cough mixtures, hospitalizations and considerable health care costs.¹ In 82 this age-group, wheezing illness is, heterogeneous and includes different 83 phenotypes with varying prognoses.²⁻⁵ Fortunately, only some children will have 84 persistent problems till school-age. The ability to predict persistence of wheeze up to 85 school-age would allow preventative and therapeutic efforts to be directed to those 86 most in need⁶ and would reassure parents of children with transient problems. It 87 would also help to select children for intervention studies aiming to alter the course 88 of disease.⁷ 89 Several groups have presented tools for prediction of later asthma in preschool 90 children⁸⁻¹⁶, but their use for primary care is limited.¹⁷ Some tools were developed in 91 92 study populations untypical for primary care. For instance, they included asymptomatic children,^{8, 10, 14, 16} children with mild symptoms, who never visited their 93 doctor,^{13, 15} or only high-risk children hospitalized for bronchiolitis.¹² Several studies 94 excluded children with chronic cough,^{13, 15} who might actually suffer from a variant of 95 asthma.^{4, 18} Some tools included predictors, such as parental education, that are not 96 easily generalizable to other populations.⁹ Other tools involve invasive 97 measurements (blood tests or skin prick tests) that might not be accepted by all 98 families in primary care.^{8, 11, 13, 14} Finally, the methods commonly used to develop the 99 prediction tools are prone to over-fitting the data.^{9, 11, 13} Over-fitting leads to reduced 100 performance when tools are applied to other populations.^{19, 20} 101 In this study we aimed to develop a simple tool to predict asthma at school-age in 102 preschool children with wheeze or chronic cough. We designed the tool for 103

application in clinical practice, particularly primary care, by: a) studying a population of symptomatic children, who had presented to the doctor for wheeze or cough; b) defining a clinically relevant outcome; c) considering only predictive factors easily assessed during a single consultation (a detailed symptom history, but no blood or skin prick tests and no repeated observations); d) developing a robust model that performs well in internal validation and relevant sensitivity analyses but does not over-fit the data and is therefore likely to be transferable to other populations.

111

112 Methods

113 Study population

We analyzed data from a population-based childhood cohort from Leicestershire, 114 UK, described in detail elsewhere.^{21, 22, 23} In brief, we recruited a representative 115 population-based sample of 6808 children of white and south Asian ethnic origin, 116 born in 1993-97. Perinatal data were collected at birth; data on growth and 117 development were acquired prospectively during childhood. Upper and lower 118 respiratory morbidity, treatments and health care utilization, family history of atopic 119 120 disease and individual and family-related exposures were assessed by repeated questionnaires (1998, 1999, 2001, 2003, 2006, 2010). The study was approved by 121 the Leicestershire Health Authority Research Ethics Committee. 122 Presentation at baseline (inclusion criteria) 123

Our analysis included all cohort children aged 1-3 years at baseline with parentreported wheeze or chronic cough (cough without colds or cough at night) with one or more visits to the doctor for wheeze or cough during the past 12 months (Fig 1, highlighted in grey). The original questions are provided in the online repository. We included chronic cough, because some children with chronic cough might suffer from

- a variant of asthma and be at risk for asthma later in life.^{4, 18} Information on
- symptoms at baseline was taken from the 1998 or the 1999 questionnaire, favoring
- the questionnaire when children were closest to age 2.0 years.
- 132 Any asthma at school-age (definition of outcome)
- 133 We defined a clinically relevant outcome as the combination of current wheeze *plus*
- use of asthma medication during the past 12 months at the age of 6-8 years, i.e. 5
- 135 years later (see online repository for original questions). Asthma medication included
- 136 short- or long-acting beta-2-agonists, inhaled corticosteroids, leukotriene receptor
- 137 antagonists or oral corticosteroids.
- 138 Choice of potential predictive factors

We used the following approach to compile the list of potential predictors. First, we 139 reviewed the literature to identify relevant risk factors for incidence or persistence of 140 childhood asthma.^{3, 24-31} From these, we only selected factors that are readily 141 available in primary care and do not require repeated observations or additional 142 investigations like blood or skin prick tests. The final list contained 24 potential 143 predictors (Table E1): demographic and perinatal data; eczema; upper and lower 144 respiratory symptoms, particularly those reflecting triggers and severity of wheeze; 145 and parental history of wheeze, asthma, bronchitis or hay fever (see online 146 repository for original questions). We did not include environmental or 147 148 socioeconomic information, because their prevalence and interpretation is likely to vary between populations and, thus, their inclusion might reduce the generalizability 149 of the tool. 150

151 Model development

¹⁵² We used LASSO-penalized logistic regression to develop the prediction model.^{32,33}

This approach allows to identify important predictors and to estimate their influence 153 on later asthma without over-fitting the data. Traditional methods used for selecting 154 predictors, such as stepwise backward or forward selection, tend to over-fit the data, 155 resulting in models that predict outcomes in the current dataset well, but become 156 unreliable in other datasets.²⁰ For our analysis, we recoded all potential predictors 157 with >2 response categories into multiple binary variables. Thus, 38 binary variables 158 derived from the 24 questions entered the variable selection process (see online 159 repository for details). LASSO regression selects predictors in the order of their 160 predictive importance. The final prediction model allows calculation of a prediction 161 score and the probability of later asthma for each child. 162

163 Model performance

We assessed our prediction model in terms of overall performance, discrimination 164 and calibration. To assess overall performance we calculated the scaled Brier 165 score,²⁰ a measure of the discrepancy between the predicted probability and the 166 actual outcome. A scaled Brier score with a value of zero means that the model 167 predicts later asthma in an individual not better than if it had been informed only by 168 the average prevalence of asthma at school-age; the maximal value of one indicates 169 perfect prediction. To determine the *discriminative ability* of the model (i.e. its ability 170 to distinguish between children with and without later asthma) we plotted the receiver 171 operating characteristics (ROC) curve and calculated the area under this curve 172 (AUC), also known as c-statistic.^{20, 34} The AUC can take on values from 0 to 1, with 1 173 being a perfectly discriminating model. Discrimination is considered not better than 174 chance if AUC=0.5, moderate if AUC is 0.6 to 0.8, and good if AUC>0.8.³⁴ 175 *Calibration* of the model (how well the predicted probabilities agree with the 176 prevalence of the outcome in subgroups of children) was tested using the Hosmer-177

178 Lemeshow goodness-of-fit-test (HL test)^{20, 35} and visualized using a calibration plot.²⁰

179 An HL test result of less than 0.05 indicates that the predicted probabilities and the

actual outcome agree poorly. In the calibration plot, a perfect calibration curve would

lie exactly on the diagonal line.

182 Internal validity

A prediction model can be validated internally to provide a more accurate estimate of model performance in other populations. As an internal validation of our model, we used the leave-one-out cross-validation method^{20, 34} assessing overall performance (Brier), discrimination (AUC), and calibration (see online repository for further

187 explanations).

188 Sensitivity analyses

189 To test the robustness of the model developed in our original study population (P0),

190 we performed sensitivity analyses using modified inclusion criteria at baseline or

191 modified definitions of the outcome, resulting in slight changes of the study

populations (P1 to P4, described in more detail in Tables E3 and E4 of the online

193 repository).

194 We first applied our existing prediction model to these modified populations and

calculated the scaled Brier score and AUC (Sensitivity analysis I). Second, we

developed new models within the slightly modified study populations P1 to P4, and

assessed their performance (Sensitivity analysis II).

198 Clinical prediction tool

199 To simplify our model to a practical tool, we considered three different approaches:

a) multiplying regression coefficients by factors 10, 5 and 3 and rounding them to the

nearest integer;²⁰ b) setting the penalty of the LASSO-penalized logistic regression

so that only a few important predictors (5 or 3) were retained, and c) considering a

model with frequency of wheeze as the only predictor.¹⁹ All these approaches aimed
to reduce the number of variables while maintaining a comparable predictive
performance.

206

207 **Results**

208 Study population

At the baseline survey, 5878 of 6808 children were aged 1-3 years. Of these, 3050 209 (52%) reported episodes of wheeze, cough without colds or cough at night in the 210 past 12 months from which 2444 reported visits to a doctor, making them eligible for 211 the study (Fig 1). For 1226 we had information on any asthma five years later. Their 212 characteristics are shown in Table I for the variables selected by the main model and 213 in Table E1 (online repository) for all potential predictors considered. At baseline, 214 215 336 children (27.4%) were aged one year, 702 (57.3%) two years and 188 (15.3%) three years. The mean prediction interval from baseline to outcome was 4.5 (± SD 216 0.5) years. At school-age, 345 (28.1%) had any asthma. 217 Table E2 in the online repository compares eligible children with and without follow-218 219 up information. The groups were comparable in many aspects (chronic cough, upper respiratory infections, eczema and parental history), but those with follow-up 220 information were more likely to be of white ethnicity and less likely to have wheeze at 221 baseline. 222 Main prediction model 223 Of the 38 binary predictors that entered variable selection, the LASSO-penalized 224 logistic regression retained 22 (Table II). The 5 most important predictors were, in 225 order of importance, shortness of breath, frequent wheeze, wheeze without colds, 226

activity disturbance by wheeze and wheeze/cough triggered by exercise. In addition,

- the model included aeroallergen-related wheeze/cough, male sex, age, birth weight,
- 229 gestational age, eczema, upper respiratory symptoms, and parental history of
- wheeze, asthma, bronchitis or hay fever.
- In the original study population, the overall performance of the main model measured
- by the scaled Brier score was 0.23 and its discriminative ability (AUC) was 0.78. In
- internal validation, these measures were comparable, 0.20 and 0.76 respectively.
- The calibration plot (Fig 2) shows good agreement between the predicted
- probabilities of later asthma and the observed frequencies in internal validation. The
- same was indicated by the Hosmer-Lemeshow test (p=0.6).
- 237 Sensitivity analyses
- 238 Sensitivity analyses I: The main model was robust to changes in baseline criteria
- (P1, P2 in Table E3). When the outcome definition was changed to wheeze plus a
- doctor's diagnosis of asthma (P3) or to moderately severe asthma (≥4 attacks plus
- inhaled corticosteroids; P4), the AUC improved to 0.80 and 0.87 respectively (P3
- and P4 in Table E3). Sensitivity analyses II: The performance of new models
- 243 developed in these alternative study populations was comparable to the main model
- for P1-P3 and slightly improved for P4 (Table E4). The selected predictors and
- estimated coefficients in the newly developed models (Table E5) were comparable to
- those of the main model. Severity-related predictors (wheeze without colds, frequent
- 247 attacks, shortness of breath, activity disturbance) gained comparatively more weight
- when predicting moderately severe asthma (P4).
- 249 Clinical prediction tool
- 250 We then simplified the model using the three planned approaches. Our preferred 251 simplification includes 10 variables (13 binary predictors), each of which contributes

with one of 3 values (1, 2 or 3) to the prediction score (Fig 3; an online version of theprediction tool is available on www.leicestercohorts.org).

This tool was derived from the original model by multiplying all regression

coefficients with 3 and rounding them to the nearest integer, dropping variables with

coefficients rounded to zero.²⁰ It had almost the same discriminative ability

257 (AUC=0.775) as the main model (AUC=0.782) (Fig.4). Other approaches to

simplification retained more predictors (making the tool complicated with little benefit)

or had reduced discriminative ability (Table E6), particularly the model with

260 frequency of wheeze only.

In internal validation, the prediction tool showed only a minor decrease in

performance compared to the main model: the scaled Brier score was 0.16 and theAUC 0.74.

The maximum score a child can attain using the prediction tool is 15, corresponding

to a 95% probability of having any asthma 5 years later (Fig 3). Sensitivity and

specificity of the tool are 0.72 and 0.71 for a score of 5, and 0.22 and 0.98 for a

score of 10 (additional performance measures are reported in Table E7). In our study

sample, 840 (69%) children were at low risk (score ≤5), 288 (23%) at medium risk

(score ≥ 6 and ≤ 9) and 98 (8%) at high risk (score ≥ 10) of any asthma 5 years later.

The percentage of children with any asthma at school age was 16%, 48% and 79%

in the low, medium and high risk groups respectively.

272

273 Discussion

274 Summary of findings

275 We have developed a new tool for predicting asthma at school-age in preschool

children who see a doctor for wheeze or cough. Our tool includes 10 predictors

- 277 representing wheeze severity and triggers, male sex, age, eczema and parental
 278 respiratory history. It showed good internal validity and is distinguished by ease of
- use in primary care and epidemiological studies.
- 280 Comparison with previous prediction models

Several prediction models have been proposed for estimating the risk of persistent 281 asthma in preschool children.⁸⁻¹⁶ Table III summarizes inclusion criteria, outcome, 282 methods used to derive the tool, predictors and performance for three tools that used 283 a similar prediction interval as ours and had a sample size of >300. In short, Castro-284 Rodriguez (Tucson Children's Respiratory Study) used data from 2-3 year-olds with 285 and without respiratory symptoms to develop two prediction tools for asthma at 286 school-age (loose and stringent asthma predictive index, API; Table III).⁸ 287 Kurukulaaratchy (Isle of Wight birth cohort) proposed a score for persistence of early 288 wheeze up to age 10.¹³ Caudri (PIAMA birth cohort), developed a clinical risk score 289 for 0-4 year-olds with wheeze or cough to predict asthma at age 7-8.9 290 The performance of these tools was comparable or slightly less than ours (Table III), 291 with a Youden index³⁶ (sensitivity + specificity -1) varying from 0.32^8 to 0.38^{13} 292 (calculated based on the maximal sum of sensitivity and specificity reported in the 293 respective studies) compared to 0.43 in our study. The Youden index ranges 294 between 0 and 1. Values close to 1 indicate large predictive effectiveness and values 295 296 close to 0 limited effectiveness. The method used to derive the APIs is difficult to replicate,⁸ while methods used for 297 the other tools ^{9, 13} (logistic regression with stepwise variable selection) tend to over-298 fit the data, i.e. the models might be overly influenced by the random variation in the 299

data used to develop them. This limits the application of the models to other

301 populations.

Only Caudri et al. performed an internal validation of their prediction model and
 reported a similar AUC (0.72) to the one we obtained (0.74). They included 8
 predictors with exact regression coefficients, while our model includes 10 predictors
 with simplified regression coefficients that facilitate calculation of individual risks in a
 clinical setting. The PIAMA risk score and the API have been tested in a small
 external population.^{19, 37}

In comparison to our tool, previous asthma prediction rules included at most two
descriptors of wheeze (out of frequency, duration or wheeze without colds).^{8-10, 14} In
addition, they relied on blood or skin prick tests,^{8, 11-13, 15} which are more time
consuming, costly and cumbersome than a detailed symptom history.

312 Socioeconomic position is a proxy measure for a variety of exposures and health

care access and might have a variable impact in different populations.⁹

314 Strengths and limitations

The main strengths of our tool are the objective approach used for its development 315 and its clinical applicability. We used a population-based sample of an adequate size 316 to develop the model. We included only children with health care visits for wheeze or 317 cough, assuring that the sample represents a clinically relevant population. We 318 defined a clinically relevant outcome measure (wheeze needing treatment). When 319 defining a more severe outcome (moderately severe asthma, defined as \geq 4 attacks 320 per year and inhaled corticosteroid treatment) the tool performed even better. All 321 predictors are easy to assess in one short primary care consultation or in a 322 questionnaire survey. We used a method that minimizes over-fitting and is less 323 affected by sampling variability compared to stepwise variable selection 324 procedures,³⁸ and we did an internal validation. Finally, our model predicts a range of 325 probabilities rather than predicting only a low or high risk as the API.⁸ 326

Like other studies,^{8, 9, 11, 13} ours relies on parent-reported questionnaire data.

However, it uses standardized questions, mostly from the ISAAC-study³⁹ and reflects 328 to some extent the clinical situation, where parents report respiratory symptoms. The 329 applied questionnaire showed good repeatability⁴⁰. Children with and without follow-330 up information were comparable (Table E2), although we cannot exclude that 331 selection bias has affected the composition of the final model. Finally, we interpreted 332 missing values in potential predictor variables as an absence of the respective risk 333 factor, which may also have affected the results. However, the number of missing 334 values did not exceed 5.8% in any of the potential predictor variables. 335

336 Meaning of the study

Our model was robust and results changed little with modifications of the inclusion criteria and outcomes. In fact, the performance improved (AUC 0.89 vs. 0.78) when we predicted moderately severe asthma, rather than any asthma. After internal validation, the AUC of main model and tool were similar to the ones before validation, suggesting that there was little over-fitting.

Our tool used only information on symptoms that can be gathered in a simple 342 anamnesis. Despite that, it had a similar or better predictive performance than 343 previous tools including more complex measurements.^{8, 11, 13-15} This suggests that a 344 detailed description of presented symptoms might predict later asthma equally well 345 as more invasive methods, including blood eosinophilia or skin prick tests.^{8, 11, 13-15} 346 Seven of 10 predictors (including the 5 strongest) describe the symptoms: frequency 347 of attacks, activity disturbance, shortness of breath, triggers (wheeze apart from 348 colds, exercise, aeroallergens) and eczema. This is consistent with the old 349 knowledge that frequent wheeze strongly predicts asthma persistence, ^{10, 41} and with 350 our previous report, showing that frequency of wheeze predicted asthma nearly as 351

well as the complicated API rule.¹⁹ In our tool, adding more symptoms (in addition to
wheeze frequency) improved the performance (AUC after internal validation 0.74 for
the tool vs. 0.57 for wheeze frequency only; Table E6). This shows that more
detailed assessment of symptoms in pre-school children improves prediction of later
asthma.

357 Future research

To further evaluate the predictive performance of the proposed tool and assess its generalizability to other populations, external validation in independent samples is necessary.³⁴ We therefore encourage the application and validation of this tool in ongoing epidemiological studies and clinical care (particularly primary care) is. Some earlier prediction models^{8, 9, 13} performed similarly in external populations, but their performance remained modest.^{15, 19, 37}

364 Compared to other prediction rules, our tool includes detailed description of symptom

severity and pattern. This raises the possibility that further refinement in the

366 description of preschool wheeze phenotype might improve precision of prediction of

later asthma. Additional gains might be made by detailed assessment of age-related

368 changes, physiological measurements (lung function, bronchial

369 hyperresponsiveness, exhaled nitric oxide, atopy), environmental, socioeconomic

and genetic risk factors.¹⁷ All this could, however, compromise the tool's simplicity.

371 Conclusions

372 This simple, low-cost and non-invasive tool has good potential for identifying pre-

373 school children at risk for later asthma and should be tested in other populations.

374 Acknowledgements

375 We thank all the children and parents of Leicestershire for participating in the study 376 and we thank Kali Tal for her editorial assistance.

377 References Stevens CA, Turner D, Kuehni CE, Couriel JM, Silverman M. The economic 378 1. impact of preschool asthma and wheeze. Eur Respir J 2003; 21:1000-6. 379 2. Henderson J, Granell R, Heron J, Sherriff A, Simpson A, Woodcock A, et al. 380 Associations of wheezing phenotypes in the first 6 years of life with atopy, 381 382 lung function and airway responsiveness in mid-childhood. Thorax 2008; 63:974-80. 383 Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ. 3. 384 Asthma and wheezing in the first six years of life. The Group Health Medical 385 Associates. N Engl J Med 1995; 332:133-8. 386 Spycher BD, Silverman M, Brooke AM, Minder CE, Kuehni CE. Distinguishing 4. 387 phenotypes of childhood wheeze and cough using latent class analysis. Eur 388 Respir J 2008; 31:974-81. 389 5. Spycher BD, Silverman M, Kuehni CE. Phenotypes of childhood asthma: are 390 they real? Clin Exp Allergy 2010; 40:1130-41. 391 6. Caudri D, Wijga AH, Smit HA, Koppelman GH, Kerkhof M, Hoekstra MO, et al. 392 Asthma symptoms and medication in the PIAMA birth cohort: evidence for 393 under and overtreatment. Pediatr Allergy Immunol 2011; 22:652-9. 394 Robertson CF, Price D, Henry R, Mellis C, Glasgow N, Fitzgerald D, et al. 7. 395 Short-course montelukast for intermittent asthma in children: a randomized 396 controlled trial. Am J Respir Crit Care Med 2007; 175:323-9. 397 Castro-Rodriguez JA, Holberg CJ, Wright AL, Martinez FD. A clinical index to 8. 398 define risk of asthma in young children with recurrent wheezing. Am J Respir 399 400 Crit Care Med 2000; 162:1403-6.

9. Caudri D, Wijga A, CM AS, Hoekstra M, Postma DS, Koppelman GH, et al. 401 Predicting the long-term prognosis of children with symptoms suggestive of 402 asthma at preschool age. J Allergy Clin Immunol 2009; 124:903-10 e1-7. 403 10. Devulapalli CS, Carlsen KC, Haland G, Munthe-Kaas MC, Pettersen M, 404 Mowinckel P, et al. Severity of obstructive airways disease by age 2 years 405 predicts asthma at 10 years of age. Thorax 2008; 63:8-13. 406 11. Evsink PE, ter Riet G, Aalberse RC, van Aalderen WM, Roos CM, van der 407 Zee JS, et al. Accuracy of specific IgE in the prediction of asthma: 408 development of a scoring formula for general practice. Br J Gen Pract 2005; 409 55:125-31. 410 12. Korppi M. Asthma predictive factors in infants with bronchiolitis: asthma risk at 411 13-20 years of age. Eur Respir J 2010; 36:221-2. 412 13. Kurukulaaratchy RJ, Matthews S, Holgate ST, Arshad SH. Predicting 413 persistent disease among children who wheeze during early life. Eur Respir J 414 2003; 22:767-71. 415 14. Lodrup Carlsen KC, Soderstrom L, Mowinckel P, Haland G, Pettersen M, 416 Munthe Kaas MC, et al. Asthma prediction in school children; the value of 417 combined IgE-antibodies and obstructive airways disease severity score. 418 Allergy 2010; 65:1134-40. 419 15. Matricardi PM, Illi S, Keil T, Wagner P, Wahn U, Lau S. Predicting persistence 420 of wheezing: one algorithm does not fit all. Eur Respir J 2010; 35:701-3. 421 16. Balemans WA, van der Ent CK, Schilder AG, Sanders EA, Zielhuis GA, 422 Rovers MM. Prediction of asthma in young adults using childhood 423 characteristics: Development of a prediction rule. J Clin Epidemiol 2006; 424 59:1207-12. 425

426 17. Savenije OE, Kerkhof M, Koppelman GH, Postma DS. Predicting who will
427 have asthma at school age among preschool children. J Allergy Clin Immunol
428 2012.

429 18. Corrao WM, Braman SS, Irwin RS. Chronic cough as the sole presenting
430 manifestation of bronchial asthma. N Engl J Med 1979; 300:633-7.

431 19. Leonardi NA, Spycher BD, Strippoli MP, Frey U, Silverman M, Kuehni CE.

Validation of the Asthma Predictive Index and comparison with simpler clinical
 prediction rules. J Allergy Clin Immunol 2011; 127:1466-72 e6.

434 20. Steyerberg E. Clinical prediction models: a practical approach to

development, validation, and updating: Springer Verlag; 2009.

436 21. Kuehni CE, Brooke AM, Strippoli MP, Spycher BD, Davis A, Silverman M.

437 Cohort profile: the Leicester respiratory cohorts. Int J Epidemiol 2007; 36:977438 85.

439 22. Dogaru CM, Strippoli MP, Spycher BD, Frey U, Beardsmore CS, Silverman M,

440 et al. Breastfeeding and lung function at school age: does maternal asthma

441 modify the effect? Am J Respir Crit Care Med 2012; 185:874-80.

23. Spycher BD, Silverman M, Egger M, Zwahlen M, Kuehni CE. Routine

vaccination against pertussis and the risk of childhood asthma: a populationbased cohort study. Pediatrics 2009; 123:944-50.

Bisgaard H, Bonnelykke K. Long-term studies of the natural history of asthma
in childhood. J Allergy Clin Immunol 2010; 126:187-97; quiz 98-9.

447 25. Frank PI, Morris JA, Hazell ML, Linehan MF, Frank TL. Long term prognosis

in preschool children with wheeze: longitudinal postal questionnaire study

449 1993-2004. BMJ 2008; 336:1423-6.

- Lowe L, Custovic A, Woodcock A. Childhood asthma. Curr Allergy Asthma 450 26. Rep 2004: 4:159-65. 451
- Matricardi PM, Illi S, Gruber C, Keil T, Nickel R, Wahn U, et al. Wheezing in 27. 452
- childhood: incidence, longitudinal patterns and factors predicting persistence. 453 Eur Respir J 2008; 32:585-92. 454
- 28. Midodzi WK, Rowe BH, Majaesic CM, Saunders LD, Senthilselvan A. 455
- Predictors for wheezing phenotypes in the first decade of life. Respirology 456 2008; 13:537-45. 457
- 29. Piippo-Savolainen E, Korppi M. Wheezy babies--wheezy adults? Review on 458
- long-term outcome until adulthood after early childhood wheezing. Acta 459
- 460 Paediatr 2008; 97:5-11.
- Sherriff A, Peters TJ, Henderson J, Strachan D. Risk factor associations with 461 30. wheezing patterns in children followed longitudinally from birth to 3(1/2) years. 462
- Int J Epidemiol 2001; 30:1473-84. 463
- 31. Van Bever HP, Desager KN, Hagendorens M. Critical evaluation of prognostic 464 factors in childhood asthma. Pediatr Allergy Immunol 2002; 13:77-83.
- 465
- 32. Friedman J, Hastie T, Tibshirani R. Regularization Paths for Generalized 466
- Linear Models via Coordinate Descent. J Stat Softw 2010; 33:1-22. 467
- 468 33. Tibshirani R. Regression shrinkage and selection via the lasso. Journal of the Royal Statistical Society. Series B (Methodological) 1996:267-88. 469
- Harrell F. Regression modeling strategies: with applications to linear models, 470 34.
- logistic regression, and survival analysis: Springer; 2001. 471
- 472 35. Hosmer DW, Hosmer T, Le Cessie S, Lemeshow S. A comparison of
- goodness-of-fit tests for the logistic regression model. Stat Med 1997; 16:965-473
- 80. 474

- 475 36. Youden WJ. Index for rating diagnostic tests. Cancer 1950; 3:32-5.
- 476 37. Rodriguez-Martinez CE, Sossa-Briceno MP, Castro-Rodriguez JA.
- 477 Discriminative properties of two predictive indices for asthma diagnosis in a
- sample of preschoolers with recurrent wheezing. Pediatr Pulmonol 2011;
- 479 46:1175-81.
- 480 38. Austin PC, Tu JV. Automated variable selection methods for logistic
- 481 regression produced unstable models for predicting acute myocardial
- infarction mortality. J Clin Epidemiol 2004; 57:1138-46.
- 483 39. Asher MI, Keil U, Anderson HR, Beasley R, Crane J, Martinez F, et al.
- International Study of Asthma and Allergies in Childhood (ISAAC): rationale
 and methods. Eur Respir J 1995; 8:483-91.
- 486 40. Strippoli MP, Silverman M, Michel G, Kuehni CE. A parent-completed
- respiratory questionnaire for 1-year-old children: repeatability. Arch Dis Child
 2007; 92:861-5.
- 489 41. Phelan PD, Robertson CF, Olinsky A. The Melbourne Asthma Study: 1964-
- 490 1999. J Allergy Clin Immunol 2002; 109:189-94.

491

492

493

494

Table I. Characteristics of the study population (N=1226) at baseline,by development of asthma 5 years later*

by development of asthmetical	na 5 years la	iter*				
		5 yrs later: Asthma (n=345)		5 yrs later: No Asthma (n=881)		
		n	(%)	n	(%)	p-value†
Demographic and perinatal	data					
Male		224	(64.9)	454	(51.5)	< 0.001
Age (years):	1	85	(24.6)		(28.5)	0.388
	2	204	. ,		(56.5)	
	3		(16.2)		· /	
Gestational age <37 weeks			(10.1)		(5.6)	0.006
Birth weight <2500 g		41	(11.9)	68	(7.7)	0.025
Wheeze-related symptoms‡						
Current wheeze		272	(78.8)	425	(48.2)	< 0.001
Wheeze without colds		127	(36.8)	95	(10.8)	< 0.001
Frequency of attacks:	0	81	(23.5)	476	(54.0)	< 0.001
	1-3	111	(32.2)	281	(31.9)	
	4-12	117	(33.9)	106	(12.0)	
	>12	36	(10.4)	18	(2.0)	
Activity disturbance:	no	141	(40.9)	649	(73.7)	< 0.001
	little	129	(37.4)	185	(21.0)	
	moderate	57	(16.5)	39	(4.4)	
	a lot	18	(5.2)	8	(0.9)	
Shortness of breath:	never	129	(37.4)	668	(75.8)	< 0.001
	sometimes		(48.1)		. ,	
	always		(14.5)		(2.6)	
Exercise-related wheeze/coug			(56.8)			< 0.001
Aeroallergen-related wheeze/c	cough	52	(15.1)	37	(4.2)	< 0.001
Other symptoms‡						
Cough without colds		233	(67.5)	536	(60.8)	0.030
Duration of colds (weeks):	<1	75	(21.7)		. ,	0.194
	1-2		(57.4)		· /	
	>2		(20.9)			
Nasal symptoms			(53.9)			< 0.001
Eczema (ever)		190	(55.1)	343	(38.9)	< 0.001
Parental history						
Wheeze, asthma or						
bronchitis:	none	142	(41.2)	499	(56.6)	< 0.001
	father	68	(19.7)			
	mother	85	· /		(20.7)	
	both				(7.3)	
Hay fever:	none		(44.1)			0.001
	father		(16.2)		. ,	
	mother	93	(27.0)			
	both	44	(12.8)	60	(6.8)	

* This table includes all predictors that were selected for the main model

† Fisher's exact test

‡ During the last 12 months

§ Wheeze or cough with running, playing, laughing or crying

		OR	Regression coefficient (RC)	Simpli- fied RC*	Order of inclusion
			Main model	Tool	
Demographic and p	erinatal data				
Male		1.48	0.394	1	9
Age: >1 year		1.19	0.171	1	16
Gestational age <37 v	veeks	1.11	0.108		18
Birth weight <2500g		1.17	0.154		17
Wheeze-related sym	ptoms†				
Current wheeze		1.18	0.163		13
Wheeze without cold	s	1.40	0.337	1	3
Frequency of attacks: Activity	>3	1.65	0.500	2	2
disturbance:	any	1.28	0.243	1	4
	moderate or a lot	1.16	0.144		7
	a lot	1.63	0.491	1	13
Shortness of breath:	sometimes or always	1.98	0.684	2	1
	always	1.56	0.442	1	6
Exercise-related whee	eze/cough‡	1.26	0.233	1	5
Aeroallergen-related	wheeze/cough	1.22	0.198	1	10
Other symptoms†					
Cough without colds		1.09	0.086		18
Duration of colds: at	least 1 week	0.97	-0.031		22
Nasal symptoms		1.17	0.157		12
Eczema (ever)		1.52	0.420	1	7
Parental history					
Wheeze, asthma or					
bronchitis:	mother or father	1.23	0.203	1	10
	both parents	1.26	0.235	1	13
Hay fever:	mother or father	1.03	0.025		21
	both parents	1.12	0.110		18

Table II. Important factors for prediction of asthma at school age in symptomatic preschool children (selected by penalized logistic regression)

* RC of the main model multiplied by 3 and rounded to the nearest integer (simplification approach where the number of variables was substantially reduced without relevant decrease in predictive performance)

† During the last 12 months

‡ Wheeze or cough with running, playing, laughing or crying

498

499 Table III. Comparison of four asthma prediction tools for preschool children

	Leicester (present study) (Leicestershire Respiratory Cohort Studies)	Tucson (API)⁸* Tucson Children's Respiratory Study	IoWBC ¹³ Isle of White Birth Cohort	PIAMA⁹ Prevention and Incidence of Asthma and Mite Allergy
N (included in analysis)	1226	776	336	2054
Inclusion criteria				
Age (y)	1-3	2-3	4	1-4
Symptoms	Health care visit due to respiratory problems plus at least one of the following symptoms in the past 12 months: Wheeze, cough without colds, cough at night	Entire cohort (including a majority of children without symptoms)	Wheeze at ages 1,2 and 4 yrs	Wheeze or cough at night without cold (or both) in the past 12 months
Outcome definition	-			
Age (y)	6-8	8	10	7-8
Prediction interval (y)	4-5	5	6	3-7
Criteria	Wheeze plus asthma medication (past 12 mo)	Doctor's diagnosis of asthma plus current wheeze, or more than 3 wheeze episodes (past 12 mo)	Current wheeze	At ages 7 and 8y: Current wheeze or prescription of inhaled corticosteroids or doctor's diagnosis of asthma (past 1 mo)
Outcome prevalence	28.1 %	13.7%	37.2%	11.7%
Predictor variables included in tool	Male sex, Age: >1y, wheeze without colds, frequent wheeze, activity disturbance, shortness of breath, exercise-related wheeze/cough†, aeroallergen-related wheeze/cough, eczema, parental asthma or wheeze bronchitis	Wheeze, frequent wheeze ⁺ , wheeze without colds, eczema, parental asthma, blood eosinophilia, allergic rhinitis	Family history of asthma, recurrent chest infections (at 2yrs), skin prick test positivity (at 4yrs), nasal symptoms (at 1yr)	Male sex, post term delivery, wheeze/dyspnea without colds, frequent wheeze, eczema, respiratory infections, inhalation medication (parents), parental education
Method used to derive tool	Penalized logistic regression	The combination of predictors was chosen that yielded the highest PPV and specificity	Stepwise backward logistic regression	Stepwise backward logistic regression
Performance measures§	Score-cutoff: ≥ 5	Loose API	Score-cutoff: ≥ 3	Score-cutoff: ≥20
Youden index ³⁶	0.43	0.32	0.38	0.36
Sensitivity (%)	72	51	53	60
Specificity (%)	71	81	85	76
PPV (%)	49	29	68	23
NPV (%)	86	91	74	94

API, Asthma Predictive Index; PPV, positive predictive value; NPV, negative predictive value.

* To have a prediction interval comparable to the one in our tool, we focused here on the API for prediction at 8 yrs

[†] Wheeze or cough with running, playing, laughing or crying

500 501 502 503 [‡] This variable is only part of the stringent API, but not of the loose API

504 \$ Reported for cut-off where sum of sensitivity and specificity pair was maximal. It is possible that a higher sum of sensitivity and specificity exists at a cut-off point that was not reported in the respective studies.

505 Figure legends

506

507 Fig 1. Wheeze, cough and health care visits in 1 to 3 year-old children.

Proportional Venn diagram for children aged 1 to 3 years, showing frequency of
health care visits due to wheeze or cough, current wheeze and chronic cough (cough
without colds or cough at night). The shaded grey represents our study population.

511

512 Fig 2. Calibration plot of main model (assessed in leave-one out cross-

validation). Children are grouped into deciles of their predicted probability. The

average predicted probability for later asthma among children within each decile is

515 plotted against the actual observed frequency (prevalence) of asthma in that group.

516 The straight line represents perfect calibration.

517

Fig 3. Asthma prediction tool. For any 1-3-year-old child seeking health care due
to wheeze or cough the applicable predictors are summed to a total score in the
upper part of the figure. The estimated probability of having asthma 5 years later is
given below for different total scores.


522


523 Fig 4. Receiver operating characteristic (ROC) curves for the main asthma

524 prediction model and for the prediction tool.

525 The dots represent sensitivity and specificity for different cutoff-values of the 526 prediction tool.


527






Asthma Prediction Tool

1.	What is the child's sex?	Female 0 Male 1
2.	How old is the child? (in years)	1 □ 0 2 □ 1 3 □ 1
3.	In the last 12 months, has the child had wheezing or whistling in the chest even without having a cold or flu?	No \square 0 Yes \square 1
4.	How many attacks of wheeze has the child had during the last 12 months?	0-3 0 >3 2
5.	In the last 12 months, how much did wheezing interfere with the child's daily activities?	No 0 A little 1 A lot 2
6.	Do these wheezing attacks cause him/her to be short of breath? So	Never 0 metimes 2 Always 3
7.	In the last 12 months, did exercise (playing, running) or emotions (laughing, crying or excitement) cause wheezing or coughing in the child?	No 0 Yes 1
8.	In the last 12 months, did contact with dust, grass, pets or other animals cause wheezing or coughing in the child?	$\begin{array}{c} No \\ Yes \\ \hline 1 \end{array} $
9.	Has the child ever had eczema?	$\begin{array}{c} \text{No} \\ \text{Yes} \\ \hline 1 \end{array} 0$
10.	Have the child's parents ever suffered from wheezing, asthma or bronchitis?	None 0 Mother 1 Father 1






1	A simple asthma prediction tool for pre-school children with wheeze or cough
2	
3	Anina M Pescatore, MSc, ¹ Cristian M Dogaru, MD, PhD, ¹ Lutz Duembgen, PhD ² ,
4	MSc, ¹ Michael Silverman, MD, ³ Erol Gaillard, MD, ³ Ben D Spycher, PhD, ^{1*}
5	Claudia E Kuehni, MD, MSc ^{1*}
6	
7	¹ Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern,
8	Switzerland;
9	² Institute of Mathematical Statistics and Actuarial Science, University of Bern, Bern,
10	Switzerland
11	³ Department of Infection, Immunity & Inflammation, University of Leicester,
12	Leicester, United Kingdom
13	* Shared last authorship
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
23	
25	Online Repository

26 Original questions used in questionnaires

27

28 **Questions used to define inclusion criteria at baseline**



31 Questions used to assess outcome at follow-up

7. Did your child take any of the following during the last	st 12 months?
• a blue inhaler (Salbutamol, Ventolin, Bricanyl or other) yes no don't know
<u>a brown or orange inhaler</u> (Pulmicort, Flixotide, Beco Beclovent or other)	otide, yes no don't know
• <u>a green inhaler (Serevent or Oxis)</u>	yes 📃 no 📃 don't know 📃
• <u>Singulair tablets</u> (Montelukast)	yes 🔄 no 🔄 don't know 📃
<u>Steroid tablets</u> (prednisolone) for attacks	yes 🔄 no 🔄 don't know 🔄



33

Questions used as potential predictive factors

8. Has your child had wheezing or whistling in the chest in the last 12 months? yes no
9. In the last 12 months, has your child had wheezing or whistling in the chest even without having a cold or flu? yes no
10. How many attacks of wheezing has your child had during the last 12 months? None 1 to 3 4 to 12 more than 12
11. In the last 12 months, how much did wheezing interfere with your child's daily activities? not at all a little a moderate amount a lot
12. Do these attacks cause him/her to be short of breath ? yes, always yes, occasionally no, never
13. In the last 12 months, how often, on average, has your child's sleep been disturbed due to wheezing? Never woken with wheezing less than one night per week one or more nights per week
14. In the last 12 months did the following things cause wheezing in your child? • exercise (playing or running) yes no don't know • laughing, crying or excitement yes no don't know • contact with pets or other animals yes no don't know • food or drinks yes no don't know
15. Does your child usually have a cough apart from colds? yes no
16. In the last 12 months, has your child had a dry cough at night , apart from a cough associated with a cold or a chest infection? yes no no
17. In the last 12 months, how many times has your child had a cold or flu? never 1 - 3 times 4 - 6 times 7 -10 times more than 10 times
18. How long does a cold usually last in your child? less than 1 week 1 to 2 weeks 2 to 4 weeks
19. In the past 12 months, has your child had ear infections? no, never yes, once yes, more than once
20. In the past 12 months, has your child had a problem with sneezing, or a runny, or blocked nose when he/she did NOT have a cold or the flu? yes no
21. Over the past 12 months, has your child snored at night? yes no
22. Has your child ever had eczema? (an itchy dry rash on arms, face and legs) yes no
In the past 12 months, has your child had eczema? yes no
23. Has the child's father ever suffered from any of the following conditions?
wheezing? yes no don't know asthma? yes no don't know
asthma? yes no don't know bronchitis? yes no don't know hayfever? yes no don't know
24. Has the child's mother ever suffered from any of the following conditions?
wheezing? yes no don't know
asthma? yes no don't know bronchitis? yes no don't know
bronchitis? yes no don't know hayfever? yes no don't know

37 **Details of statistical methods**

38 Development of the main prediction model

We used the R package glmnet to fit the penalized logistic regression. The 39 parameter alpha was set to 1 so that only a LASSO type penalty was included. This 40 tends to retain only the most influential predictors. The parameter lambda, which 41 42 determines the magnitude of the penalty was set to a value that maximized the area under the receiver operating characteristic curve of resulting predictions in 10-fold 43 cross-validation¹. All potential predictors with more than 2 response categories were 44 coded as binary variables. If the original categories were ordered, these 45 dichotomous variables represented all possible cut-off points separating lower from 46 higher categories. For instance, frequency of wheezing episodes in the past 12 47 months (0, 1-3, 4-12, >12) was coded into 3 binary variables indicating >0, >3, and 48 >12 episodes respectively. This procedure resulted in 38 binary variables entering 49 50 variable selection. Data were prepared using Stata 11.0 and analysed using R version 2.12.2. We used the R package ROCR to assess discrimination and the 51 functions hosmerlem and val.prob.ci to assess calibration². 52

53

54 Clinical prediction tool

To simplify our model to a practical tool, we considered three different approaches: a) multiplying regression coefficients by factors 10, 5 and 3 and rounding them to the nearest integer;²⁰ b) setting the penalty of the LASSO-penalized logistic regression so that only a few important predictors (5 or 3) were retained, and c) considering a model with frequency of wheeze as the only predictor.¹⁹ All these approaches aimed to reduce the number of variables while maintaining a comparable predictive performance.

In Table E7 the performance of these tools are compared with the main model in
sample (sample used for model development) and by internal validation (see below).
In a final step, we recalibrated the probabilities for later asthma of the preferred tool
by re-running a logistic regression of the outcome on simplified scores.

66

67 Internal validation

To assess the reliability of our result of model performance within our study sample 68 (i.e. to test its repeatability within our development sample) we tested our model in 69 70 leave-one-out cross-validation. The first step in this technique is to omit the first of total n observations and to use the remaining n-1 observations from the entire study 71 sample to develop a new model. Using this new model, the probability for later 72 asthma is estimated for the one observation left out before. In total, this procedure is 73 74 repeated n times, each time omitting an observation that has not previously been left out. In the end, internal validity of the model is tested based on these estimated 75 probabilities. 76

Because the purpose was to test the main model's predictive performance and not how the method performs (including variable selection), we chose leave-one-out cross-validation as an internal validation technique that aims to fit models which are very similar to the main model. Other approaches, such as bootstrapping, would result in fitting models that are less similar to the main model, and thus would have tested the repeatability of the method (variable selection approach and estimation of regression coefficients) rather than have validated the main model itself.

84

85

86 **References**

87		
88	1.	Friedman J, Hastie T, Tibshirani R. Regularization Paths for Generalized Linear
89		Models via Coordinate Descent. J Stat Softw 2010; 33:1-22.
90	2.	Homepage for clinical prediction models. [Cited 2011 November 9.] Available from
91		http://survey.erasmusmc.nl/wiki/mgz-
92		clinpred/doku.php?id=rcode_and_data:chapter15.
93		
94		
95		

Question			Total study population (N=1226)		5 yrs later: Asthma (N=345)		5 yrs later: No Asthma (N=881)			
number*			n	(%)	n	(%)	n	(%)	p-value [.]	
	Demographic and perinata	l data		(70)		(70)		(70)	p-value	
	Male		678	(55.3)	224	(64.9)	454	(51.5)	< 0.001	
	Age (years)	1		(27.4)	85	(24.6)	251		0.388	
		2	702	(57.3)	204	(59.1)	498	(56.5)		
		3	188	(15.3)	56	(16.2)	132	(15.0)		
	Gestational age <37 weeks		84	(6.9)	35	(10.1)	49	(5.6)	0.006	
	Birth weight <2500 g			(8.9)	41	(11.9)	68		0.025	
	South Asian ethnicity (versus	s white)		(25.8)		(22.6)		(27.0)	0.127	
	Wheeze-related symptoms:	:								
8	Current wheeze		697	(56.9)	272	(78.8)	425	(48.2)	< 0.001	
9	Wheeze without colds		222	(18.1)	127	(36.8)	95	(10.8)	< 0.001	
10	Frequency of attacks:	0	557	(45.4)	81	(23.5)	476	(54.0)	< 0.001	
		1-3	392	(32.0)	111	(32.2)	281	(31.9)		
		4-12	223	(18.2)	117	(33.9)	106	(12.0)		
		>12	54	(4.4)	36	(10.4)	18	(2.0)		
11	Activity disturbance:	no	790	(64.4)	141	(40.9)	649	(73.7)	< 0.001	
	-	little	314	(25.6)	129	(37.4)	185	(21.0)		
		moderate	96	(7.8)	57	(16.5)	39	(4.4)		
		a lot	26	(2.1)	18	(5.2)	8	(0.9)		
12	Shortness of breath:	never	797	(65.0)	129	(37.4)	668	(75.8)	< 0.001	
		sometimes	356	(29.0)	166	(48.1)	190	(21.6)		
		always	73	(6.0)	50	(14.5)	23	(2.6)		
13	Sleep disturbance:	never	790	(64.4)	148	(42.9)	642	(72.9)	< 0.001	
		<1	269	(21.9)	122	(35.4)	147	(16.7)		
		>=1	167	(13.6)	75	(21.7)	92	(10.4)		
14	Exercise-related wheeze/coug	gh§	482	(39.3)	196	(56.8)	286	(32.5)	< 0.001	
14	Aeroallergen-related wheeze	/cough	89	(7.3)	52	(15.1)	37	(4.2)	< 0.001	
14	Food-related wheeze/cough		186	(15.2)	54	(15.7)	132	(15.0)	0.791	
	Other symptoms‡									
15	Cough without colds		769	(62.7)	233			(60.8)	0.030	
16	Cough at night		631	(51.5)	190	(55.1)	441	(50.1)	0.127	
17	Frequency of colds:	<4	447	` '	101	(29.3)		(39.3)	0.001	
		4-6	461		134	. ,	327	(37.1)		
		>6	318	. ,	110	(31.9)	208	. ,		
18	Duration of colds (weeks):	<1	278	(22.7)	75	(21.7)	203	(23.0)	0.194	
		1-2		(59.6)	198	(57.4)	533	(60.5)		
10		>2	217	(17.7)	72	(20.9)	145	(16.5)	0.000	
19	Ear infection(s):	0	599	(48.9)	151	(43.8)	448	(50.9)	0.020	
		1	351	,	99	(28.7)	252	. ,		
•		>1		(22.5)	95	(27.5)	181	. ,	0.63	
20	Nasal symptoms			(43.7)	186	(53.9)	350	. ,	< 0.001	
21	Snoring			(71.8)	267	(77.4)	613	(69.6)	0.006	
22	Eczema (ever)		533	(43.5)	190	(55.1)	343	(38.9)	< 0.001	

Table E1. Characteristics of the study population (N=1226) at baseline by development ofasthma 5 years later (all potential predictors considered in the analysis)

	Parental history Wheeze, asthma or			
23/24	bronchitis:	none	641 (52.3) 142 (41.2) 499 (56.6) <0.001	
		father	204 (16.6) 68 (19.7) 136 (15.4)	
		mother	267 (21.8) 85 (24.6) 182 (20.7)	
		both	114 (9.3) 50 (14.5) 64 (7.3)	
23/24	Hay fever:	none	626 (51.1) 152 (44.1) 474 (53.8) 0.001	
		father	200 (16.3) 56 (16.2) 144 (16.3)	
		mother	296 (24.1) 93 (27.0) 203 (23.0)	
		both	104 (8.5) 44 (12.8) 60 (6.8)	

* See Online Repository: Original questions used in questionnaires

† Fisher's exact test

‡ During the last 12 months

§ Wheeze or cough with running, playing, laughing or crying

Table E2. Characteristics of children at baseline, by availability of follow-up information (N=2444)

		Follow-up information available (N=1226)		infor 1 ava	ow-up mation not ilable =1218)	
Dama ang kisanda aning ta	1 4040	n	(%)	n	(%)	p-value*
Demographic and perinata	l data					
Male		678	(55.3)	633	(52.0)	0.105
Gestational age <37 weeks		84	(6.9)	86	(7.1)	0.874
Birth weight <2500 g		109	(8.9)	86	(7.1)	0.101
South Asian ethnicity (versu	s white)	316	(25.8)	386	(31.7)	0.001
Wheeze-related symptoms	ŕ					
Current wheeze		697	(56.9)	762	(62.6)	0.004
Wheeze without colds		222	(18.1)	272	(22.3)	0.010
Frequency of attacks:	0	557	(45.4)	482	(39.6)	0.012
	1-3	392	(32.0)	419	(34.4)	
	4-12	223	(18.2)	269	(22.1)	
	>12	54	(4.4)	48	(3.9)	
Activity disturbance:	no	790	(64.4)	725	(59.5)	0.044
	little	314	(25.6)	371	(30.5)	
	moderate	96	(7.8)	91	(7.5)	
	a lot	26	(2.1)	31	(2.5)	
Shortness of breath:	never	797	(65.0)	749	(61.5)	0.193
	sometimes	356	(29.0)	387	(31.8)	
	always	73	(6.0)	82	(6.7)	
Sleep disturbance:	never	790	(64.4)	728	(59.8)	0.059
	<1	269	(21.9)	304	(25.0)	
	>=1	167	(13.6)	186	(15.3)	
Exercise-related wheeze/cou	gh‡	482	(39.3)	531	(43.6)	0.033
Aeroallergen-related wheeze	/cough	89	(7.3)	104	(8.5)	0.261
Food-related wheeze/cough		186	(15.2)	196	(16.1)	0.540
Other symptoms†						
Cough without colds		769	(62.7)	798	(65.5)	0.152
Cough at night		631	(51.5)	612	(50.2)	0.571
Frequency of colds:	<4	447	(36.5)	420	(34.5)	0.498
	4-6	461	(37.6)	484	(39.7)	
	>6	318	(25.9)	314	(25.8)	
Duration of colds (weeks):	<1	278	(22.7)	268	(22.0)	0.897
	1-2	731	(59.6)	737	(60.5)	
	>2	217	(17.7)	213	(17.5)	
Ear infection(s):	0	599	(48.9)	613	(50.3)	0.481
	1	351	(28.6)	322	(26.4)	

	>1	276	(22.5)	283	(23.2)	
Nasal symptoms		536	(43.7)	569	(46.7)	0.143
Snoring		880	(71.8)	877	(72.0)	0.928
Eczema (ever)		533	(43.5)	548	(45.0)	0.464
Parental history						
Wheeze, asthma or						
bronchitis:	none	641	(52.3)	647	(53.1)	0.581
	father	204	(16.6)	178	(14.6)	
	mother	267	(21.8)	276	(22.7)	
	both	114	(9.3)	117	(9.6)	
Hay fever:	none	626	(51.1)	646	(53.0)	0.702
	father	200	(16.3)	199	(16.3)	
	mother	296	(24.1)	271	(22.2)	
	both	104	(8.5)	102	(8.4)	

* Fisher's exact test

† During the last 12 months

‡ Wheeze or cough with running, playing, laughing or crying

98

Table E3. Sensitivity analysis I: Testing performance of main asthma prediction model in alternative study populations

		ne criter vear-olds		Outcom 5 y	ie defini vrs later	tion					
Study population	Health care visit and any wheeze or chronic cough	Health care visit and any wheeze	Any wheeze	Any wheeze and asthma medication	Any wheeze and ever doctor-diagnosed asthma	>4 episodes of wheeze and inhaled corticosteroids	N Total	n Outcome	(%)	Brier (scaled)	AUC*
P0 (used for main model)	\checkmark		l	\checkmark			1226	345	(28.1)	0.23	0.78
P1			✓	\checkmark			769	285	(37.1)	0.21	0.77
P2		\checkmark		\checkmark			697	272	(39.0)	0.22	0.77
P3	\checkmark		l		\checkmark		1239	331	(26.7)	0.25	0.80
P4	\checkmark					√	1053	71	(6.7)	-0.51†	0.87

Baseline and outcome criteria refer to the past 12 months, if not otherwise stated

*Area under receiver operating characteristic curve

[†] The negative scaled Brier score is due to the large difference in the prevalence of the outcome in P0 and P4. A simple recalibration without changing the score would lead to a scaled Brier score of 0.24

Table E4. Sensitivity analysis II: Testing performance of newly developed asthma prediction models based on alternative study populations

		e criteri ear-olds	a	Outcome 5 yr	defin i s later	ition						
Study population	Health care visit and any wheeze or chronic cough	Health care visit and any wheeze		Any wheeze and asthma medication	Any wheeze and ever doctor-diagnosed asthma	>4 episodes of wheeze and inhaled corticosteroids	No. of binary predictors in the model	N Total	n Outcome	(%)	Brier (scaled)	AUC*
P0 (used for main model)	\checkmark			\checkmark			22	1226	345	(28.1)	0.23	0.78
P1		•		✓			25	769	285	(37.1)	0.22	0.77
P2	,	\checkmark		\checkmark	,		23	697	272	(39.0)	0.23	0.78
P3	\checkmark				\checkmark		26	1239	331	(26.7)	0.26	0.81
P4	\checkmark					\checkmark	20	1053	71	(6.7)	0.28	0.89

Baseline and outcome criteria refer to the past 12 months, if not otherwise stated

*Area under receiver operating characteristic curve

100 101

TABLE E5. Selected predictors in sensitivity analysis II and corresponding ORs

		Main model*	(alter	New models (alternative populations)					
			P1†	P2‡	P3§				
		Odds Ratio				P4			
		(OR)	OR	OR	OR	OR			
Demographic and per	rinatal data								
Male		1.48	1.43	1.49	1.68	1.00			
Age (years)	≥2	1.19	1.53	1.51	1.28	1.00			
	3	1.00	1.00	1.01	1.06	0.95			
Gestational age <37 we	eeks	1.11	1.13	1.00	1.16	1.00			
Birth weight <2500 g		1.17	1.18	1.28	1.34	1.00			
South Asian ethnicity ((versus white)	1.00	1.00	1.00	1.00	0.53			
Wheeze-related symp	toms¶								
Current wheeze		1.18	1.00	1.00	1.59	1.46			
Wheeze without colds		1.40	1.55	1.45	1.42	2.11			
Frequency of attacks	≥1	1.00	1.00	1.00	1.05	1.00			
1 5	>3	1.65	1.53	1.60	1.37	1.16			
	>12	1.00	1.00	1.00	1.00	2.10			
Activity disturbance	any	1.28	1.30	1.25	1.28	1.49			
5	moderate or a lot	1.16	1.31	1.17	1.14	1.00			
	a lot	1.63	1.94	1.87	1.81	2.18			
Shortness of breath	sometimes or always	1.98	1.90	1.91	1.84	2.06			
	always	1.56	1.40	1.41	2.10	2.70			
Sleep disturbance	$\geq 1/\text{week}$	1.00	1.00	1.00	1.10	1.00			
Sheep distaiounee	>1/week	1.00	1.00	1.00	1.00	1.20			
Exercise-related wheez		1.26	1.09	1.15	1.40	1.27			
Aeroallergen-related w	•	1.22	1.05	1.04	1.33	1.00			
Food-related wheeze/c	-	1.00	1.03	1.02	0.97	1.00			
Other symptoms¶									
Cough without colds		1.09	1.10	1.07	1.16	1.37			
Cough at night		1.00	1.12	1.13	1.06	1.00			
Frequency of colds	>3	1.00	1.00		1.00	1.06			
requency of colds	>6	1.00	0.97	1.00	1.00	1.00			
Duration of colds	>1	0.07	0.80	0.00	0.00	1.00			
(weeks)	≥ 1	0.97	0.89	0.90	0.80	1.00			
Γ_{aa} information (a)	>2	1.00	1.00	1.00	1.00	1.00			
Ear infection(s)	<u>≥1</u>	1.00	1.13	1.00	1.00	1.00			
Nacal annatana	>1	1.00	1.00	1.00	1.00	1.00			
Nasal symptoms		1.17	1.14	1.13	1.18	1.14			
Snoring		1.00	1.00	1.00	1.00	1.00			
Eczema (ever)		1.52	1.42	1.50	1.39	1.62			
Parental history									
Wheeze or bronchitis	mother or father	1.23	1.14	1.06	1.45	1.07			
	mother or both	1.00	1.00	1.00	1.00	1.00			
	both parents	1.26	1.57	1.36	1.39	2.02			
Hay fever	mother or father	1.03	1.00	1.00	1.00	1.09			
	mother or both	1.00	1.05	1.01	1.00	1.00			

both parents 1.12 1.28 1.37 1.41 1.34

Baseline and outcome criteria refer to the past 12 months, if not otherwise stated * Inclusion criteria: 1-3 year-olds with health care visit plus either wheeze or cough without

colds or cough at night;

Outcome: Wheeze plus asthma medication at age 6-8 yrs

† Inclusion criterion: 1-3 year-olds with wheeze; Outcome: same as in main model

‡ Inclusion criteria: 1-3 year-olds with health care visit plus wheeze; Outcome: same as in main model

§ Inclusion criteria: same as in main model; Outcome: Current wheeze plus doctor's diagnosis of asthma (ever) at age 6-8 yrs

" Inclusion criteria: same as in main model; Outcome: >4 episodes of wheeze and using inhaled corticosteroids

¶ During the last 12 months

**Wheeze or cough with running, playing, laughing or crying

103 104

105

Simplification approach		No. of binary predictors in the model	Brier scor	e (scaled)	AUC*		
Main model	no simplification	22	befor€≩al∥	aft 0 r2@al¶	beford &al	aft 0 r76al¶	
Rounded model†	factor 10	20	0.23	0.19	0.78	0.75	
	factor 5	19	0.23	0.21	0.78	0.77	
	factor 3††	13	0.22	0.16	0.78	0.74	
Reduced model	first five predictors only‡	5	0.14	0.13	0.75	0.64	
	first three predictors only§	3	0.12	0.11	0.73	0.60	
Frequent wheeze	e only**	3	0.13	0.12	0.70	0.57	

Table E6. Predictive performance of simplified versions of the main asthma prediction model

* Area under receiver operating characteristics curve

†: Using simplified regression coefficients of the model (regression coefficients of main model multiplied by 10, by 5 or by 3, respectively, and rounded to the next integer)

‡ Shortness of breath due to wheeze, frequent wheeze episodes (>3), wheeze without colds, activity disturbance due to wheeze; exercise-related wheeze/cough

§ Shortness of breath due to wheeze, frequent wheeze episodes (>3), wheeze without colds

" Before internal validation: assessment using same sample as used to develop the model

¶ After internal validation: assessment using leave-one-out crossvalidation

** A 4-level variable coded as 3 binary dummy variables; analysis using logistic regression without penalization **††** Preferred model

cutoff-values (crossvalidation						
Score-cutoff	Sensitivity	Specificity	PPV	NPV	LR+	LR-
0	>0.99	< 0.01	0.28	NA	1.00	*
1	>0.99	0.02	0.29	0.95	1.02	0.12
2	0.96	0.14	0.30	0.89	1.11	0.30
3	0.91	0.37	0.36	0.92	1.45	0.23
4	0.79	0.57	0.42	0.87	1.84	0.37
5	0.72	0.71	0.49	0.86	2.47	0.40
6	0.62	0.80	0.55	0.84	3.18	0.47
7	0.52	0.88	0.62	0.82	4.19	0.55
8	0.42	0.92	0.68	0.80	5.53	0.63
9	0.33	0.96	0.77	0.79	8.32	0.70
10	0.22	0.98	0.79	0.76	9.36	0.80
11	0.13	0.99	0.80	0.74	10.45	0.88
12	0.06	>0.99	0.83	0.73	12.77	0.95
13	0.02	>0.99	0.89	0.72	20.43	0.98
14	0.01	>0.99	>0.99	0.72	*	0.99
15	< 0.01	>0.99	NA	0.72	*	>0.99

 Table E7. Performance measures of the prediction tool for different

PPV, positive predictive value; *NPV*, negative predictive value; *LR*+, likelihood ratio positive; *LR*-, likelihood ratio negative

Sensitivity, Specificity, PPV, NPV: restricted to values between 0 and 1

* Great uncertainty of estimate due to sensitivity and specificity close to 0 or 1